Saturday, November 22, 2025


Ancient arctic adaptations may influence modern disease risk




University of Copenhagen





Over the past 25 years, Greenlanders have experienced a dramatic increase in cardiometabolic diseases, including type 2 diabetes and cardiovascular disease. Scientists have already linked their increased risk of these diseases to genetic variants that are common in the Inuit Greenlandic population but rare in other populations. These variants likely provided survival advantages in the harsh Arctic environment and with traditional diets based on marine mammals, which are rich in protein and polyunsaturated fatty acids.

What is less well understood is how these variants increase the risk of disease. Our genome plays a crucial role in regulating the levels of proteins in the bloodstream, which in turn control inflammation, metabolism, immune responses, and cardiovascular function. If a genetic variant affects both protein levels and disease risk, it suggests that the protein is likely involved in the disease's development.

In a new study published in the American Journal of Human Genetics, an international team of researchers identified 251 genetic variants that significantly affect circulating protein levels in Greenlanders. The study revealed that genetic control over certain proteins is substantially stronger in Greenlandic Inuit than in Europeans, and uncovered 70 previously unreported associations. Their discoveries provide crucial insights into how Arctic-adapted genes influence modern disease risk.

"By understanding how genetic variants regulate proteins in the blood, we can identify new drug targets and understand why certain populations are more susceptible to specific diseases. This is especially important for populations like Greenland, where unique genetic adaptations that once provided survival advantages now contribute to elevated disease risks,” said Professor Torben Hansen from the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, who co-led the study.

Linking ancient adaptations to modern disease

In the study, the scientists analyzed blood samples from 3,707 Greenlandic individuals collected through population health surveys conducted between 1998 and 2019. Using advanced proteomics technology, they measured levels of 177 proteins related to inflammation and cardiovascular health. They then examined how genetic variation across the genome influenced these protein levels.

The research revealed several significant associations between Arctic-enriched genetic variants and disease-related proteins. The CPT1A variant, which likely enabled the Inuit to process traditional high-fat Arctic diets, was associated with lower levels of 55 inflammatory and cardiovascular proteins in carriers. The TBC1D4 variant, which contributes to up to 10% of diabetes cases in Greenland, is associated with altered levels of nine immune-related proteins, including key inflammatory markers. Additionally, the researchers discovered a novel genetic variant affecting IL-6 levels that was associated with a 31% increased risk of cardiovascular disease in Greenlanders.

Importantly, this study found that genetic control over protein levels is stronger in Greenlandic Inuit than in Europeans. For certain key proteins, such as IL-27 and Gal-9, genetic variants account for 30-44% of their levels in Greenlanders but less than 20% in Europeans. This demonstrates that isolated populations can harbor high-impact genetic variants that reveal fundamental biological mechanisms invisible in more commonly studied populations.

The Case for Diverse Genomic Research

This research builds on a comprehensive genetic study of Greenlanders published in Nature earlier this year. While that study mapped the population's unique genetic architecture and identified disease-associated variants, this new work reveals the biological mechanisms behind these associations and demonstrates how Arctic-adapted genetic variants influence circulating protein levels and disease development.

Nearly all previous studies linking genetic variants to protein levels have focused on individuals of European ancestry, which leaves a significant gap in scientific knowledge. By revealing how Arctic-adapted variants influence protein levels and disease risk, this study demonstrates that genetic architecture varies substantially across populations. In so doing, it provides insights relevant to both Greenlandic health interventions and global understanding of cardiometabolic disease mechanisms.

“Indigenous and underrepresented populations have been largely excluded from genomic research. Without studying diverse populations, we miss critical pieces of human biology and perpetuate health disparities," said Sara Stinson, who carried out the research while she was a Postdoc at the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen and co-first author of the study together with Postdoc Renzo Balboa from the University of Copenhagen.

About the Study

The research was conducted by an international team led by the Novo Nordisk Foundation Center for Basic Metabolic Research and the Department of Biology at the University of Copenhagen, in collaboration with the National Institute of Public Health at the University of Southern Denmark, the Greenland Center for Health Research, and Steno Diabetes Center Greenland.

The study was funded by the Novo Nordisk Foundation, the Independent Research Fund Denmark, and other sources. Data were collected through three population-based health surveys conducted in Greenland with ethics approval and participant consent.

Working together to combat the spread of antibiotic resistance

The BfR participates in an interdisciplinary monitoring approach.



BfR Federal Institute for Risk Assessment




OHIS stands for One Health Integrated Surveillance, i.e. the monitoring of antibiotic resistance in the sense of a holistic, interdisciplinary One Health strategy. In addition to the BfR, the Robert Koch Institute (RKI), the Friedrich Loeffler Institute (FLI), the Federal Environment Agency (UBA) and the German Federal Office of Consumer Protection and Food Safety (BVL) are also involved in the network.

The group was formed in 2023 as part of the government's German Antibiotic Resistance Strategy (DART 2030). DART 2030 outlines six areas of action for halting the spread of antibiotic resistance at national level and through international cooperation. In addition to prevention, the appropriate use of antibiotics, research and development, "surveillance and monitoring" is one of the key areas of action. The aim of interdisciplinary surveillance is, among other things, to identify trends and developments in antibiotic resistance so that targeted measures can be taken at an early stage and subsequently assessed. One of the goals of DART 2030 is for the OHIS group to set up a website linking data from the individual sectors.

The BfR is involved in various aspects of the fight against antibiotic resistance. For example, the institute is home to the National Reference Laboratory (NRL) for Antibiotic Resistance. Its most important task is to collect comparable data on antibiotic resistance in zoonotic agents and other bacteria that pose a hazard to public health. The results are summarised in the annual zoonosis report and forwarded to the European Food Safety Authority (EFSA). Since 2023, this and other monitoring data has also been made available to experts and the interested public via the ZooNotify internet portal.

Another key activity of the BfR is the collection and assessment of antibiotic consumption quantities in cattle, pigs, chickens and turkeys, as well as the frequency of treatment in certain animal production types. The annual evaluation of the data forms the basis for the competent authorities to take measures to protect consumers.

The OHIS meeting, to which the Federal Ministry of Health (BMG), the Ministry of Agriculture (BMLEH) and the Ministry of the Environment (BMUKN) are also invited, is organised by the BVL and supports the motto of this year's WAAW, "Act Now: Secure Our Present, Protect Our Future."

Further information on the use of antibiotics and the development of resistance

Topic page on the use of antibiotics in livestock
https://www.bfr.bund.de/en/food-safety/assessment-of-microbial-risks-in-foods/use-of-antibiotics-in-livestock/

Topic page on antibiotic resistance
https://www.bfr.bund.de/en/research/research-fields/microbiology/antibiotic-resistance/

Zoonotify
https://zoonotify.bfr.berlin/explanations?lang=en

About the BfR

The German Federal Institute for Risk Assessment (BfR) is a scientifically independent institution within the portfolio of the German Federal Ministry of Agriculture, Food and Regional Identity (BMLEH). It protects people's health preventively in the fields of public health and veterinary public health. The BfR provides advice to the Federal Government as well as the Federal States (‘Laender’) on questions related to food, feed, chemical and product safety. The BfR conducts its own research on topics closely related to its assessment tasks.

 

New collection of bacteria-eating viruses to tackle hospital superbug




University of Southampton

Samples in the phage collection. Transparent dots show where the phages have been effective in breaking down bacteria. 

image: 

Samples in the phage collection. Transparent dots show where the phages have been effective in breaking down bacteria.

view more 

Credit: University of Southampton





An international team of researchers led by the University of Southampton and funded by Bowel Research UK have comprehensively catalogued a new collection of bacteria-eating viruses called phages sourced, in part, from hospital wastewater.

The phages in the collection have been shown to be effective against different strains of Klebsiella pneumoniae - a type of bacteria that has become a serious threat in hospitals because of its growing resistance to multiple antibiotics.

While phages that target Klebsiella are increasingly being documented in research, their clinical use has been slowed by fragmented access to data on phages and which bacteria they target.

To speed up research and treatment development, the researchers have made the new collection open source and publicly available at www.klebphacol.org. It’s been detailed in a paper published today (20 November 2025) in Nucleic Acids Research.

Dr Franklin Nobrega, Associate Professor in Microbiology at the University of Southampton and project lead, whose work is supported by Bowel Research UK, said: “Making the Klebsiella Phage Collection open access is crucial. It means scientists everywhere can both use and build on it. Researchers can request samples of phages and bacterial strains for their own studies, compare results across labs, and even contribute new phages and strains to the collection.

“By sharing these resources openly, we’re breaking down barriers that have slowed progress and creating a truly collaborative global effort to tackle antibiotic resistance.”

Klebsiella can cause serious infections such as pneumonia, bloodstream infections, and urinary tract infections—particularly in hospital patients or people with weakened immune systems.

Health officials are particularly concerned as some strains are developing resistance to multiple antibiotics, including those used as a last resort when others have failed.  

New phage family discovered

Different phages work a bit like different keys - each one can only “unlock” (infect) certain strains of the bacteria.

The Klebsiella Phage Collection fully characterises 52 different phages, alongside 74 strains of Klebsiella. These phages come from five viral families, including a newly discovered group linked to the human gut.

Previous studies have suggested that some strains of Klebsiella are associated with inflammation in the gut, potentially worsening inflammatory bowel disease (IBD).

Dr Nobrega commented: “Some of these newly identified phages can be found in people’s guts across the world, in everyone from pre-term babies to older adults. They were found in healthy guts, so we know they are important for good gut health.

“The presence or absence of certain phages can predict how severe diseases like bowel cancer and IBD are going to be, so our discovery, along with our new library of phages, paves the way for more research to understanding more about these diseases and ultimately improve treatments.”

Kathryn Pretzel-Shiels, CEO of Bowel Research UK, said: “Research like this is crucial in understanding the best way to harness the power of the microbiome to prevent and treat bowel conditions. We're enabling more research to help scientists fully understand the role our gut microbiome plays in maintaining a healthy gut and protecting us from bowel disease.”

The hope is that this phage library will not only support new treatments but also improve understanding of how phages and bacteria interact -knowledge that could prove vital in the fight against antibiotic resistance.

KlebPhaCol:  A community-driven resource for Klebsiella research identified a novel phage family is published in Nucleic Acids Research and is available online.

Ends

Contact

Steve Williams, Media Manager, University of Southampton, press@soton.ac.uk or 023 8059 3212.

Helen Pope, Communications Consultant Bowel Research UK, press@bowelresearchuk.org or 07879 818247

Notes for editors

  1. KlebPhaCol: A community-driven resource for Klebsiella research identified a novel phage family is published in Nucleic Acids Research. It is available here: KlebPhaCol: a community-driven resource for Klebsiella research identified a novel phage family | Nucleic Acids Research | Oxford Academic
  2. For Interviews, please contact Steve Williams, Media Manager, University of Southampton press@soton.ac.uk or 023 8059 3212.
  3. Images available here: https://safesend.soton.ac.uk/pickup?claimID=aZ5sTfSTEv5MP7zo&claimPasscode=r393Ndzqcx8qbj2ov
  4. Video for bulletins available here: https://safesend.soton.ac.uk/pickup?claimID=M96oYMtAaAHZBd8z&claimPasscode=a89ZZ6QYk777tgqW

Additional information

The University of Southampton drives original thinking, turns knowledge into action and impact, and creates solutions to the world’s challenges. We are among the top 100 institutions globally (QS World University Rankings 2025). Our academics are leaders in their fields, forging links with high-profile international businesses and organisations, and inspiring a 24,000-strong community of exceptional students, from over 135 countries worldwide. Through our high-quality education, the University helps students on a journey of discovery to realise their potential and join our global network of over 300,000 alumni. www.southampton.ac.uk

www.southampton.ac.uk/news/contact-press-team.page

Follow us on X: https://twitter.com/UoSMedia

About Bowel Research UK

Bowel Research UK is funding life-changing research into bowel cancer and other bowel diseases. Every year over 16,000 people die from bowel cancer in the UK and over a million suffer from bowel disease. By researching cutting edge treatments and investing in the best science, we’re saving and improving people’s lives We’re the UK’s leading specialist bowel cancer and bowel disease research charity and our research is saving and improving lives. https://www.bowelresearchuk.org/